Consorci Mar Parc De Salut De Barcelona

At Consorci Mar Parc De Salut De Barcelona investigators are testing innovative anesthesia and analgesia methods to improve patient comfort during surgery and procedural care.

• Evaluation of fast‑track anesthetic protocols for pediatric appendectomy
• Assessment of multimodal pain management in postoperative recovery
• Safety monitoring of new regional block techniques

The department supports 20 active trials with a multidisciplinary team of 32 investigators.

Research focuses on the development of novel therapeutic agents across a spectrum of diseases, ranging from skin disorders to oncology.

• Combination therapy for moderate to severe atopic dermatitis
• Targeted oral agents for resistant hypertension
• Anticancer drug evaluation in advanced solid tumors

Clinical studies are conducted under strict ethical standards, enhancing treatment options for patients.

The group is refining operative techniques to reduce hospital stay and complications, including a fast‑track model for complex abdominal surgery.

• Fast‑track therapeutic strategy for complicated acute appendicitis
• Evaluation of minimally invasive laparoscopic procedures
• Post‑operative pain control using non‑pharmacologic interventions

Surgical innovation aligns with the site’s commitment to patient‑centered care.

Studies address challenging bacterial infections, such as multidrug‑resistant urinary and prostate infections, to identify effective oral and intravenous therapies.

• Oral fosfomycin‑tromethamol for acute multidrug‑resistant Escherichia coli prostatitis
• Inhaled antibiotic strategies for chronic bronchial infection in bronchiectasis
• Monitoring of antimicrobial resistance patterns in clinical isolates

The work contributes to improving outcomes for patients with resistant bacterial diseases.

Research targets heart‑related conditions, including heart failure, hypertension, and pulmonary hypertension with preserved ejection fraction, to enhance quality of life and functional capacity.

• Effect of a novel biologic on health‑related quality of life in heart failure
• Blood pressure reduction with adjunctive antihypertensive agents
• Exercise tolerance improvement using levosimendan in PH‑HFpEF patients

Cardiovascular trials integrate patient‑reported outcomes to capture real‑world benefits.

The site explores therapeutic options for genetic disorders, notably Fragile X syndrome, aiming to address core cognitive and behavioral challenges.

• Safety and tolerability assessment of a novel agent in adult males with Fragile X syndrome
• Biomarker analysis for treatment response in hereditary neurodevelopmental conditions
• Long‑term follow‑up of developmental outcomes in treated participants

Findings may inform future strategies for rare hereditary diseases.

Investigations include management of gastro‑esophageal symptoms, focusing on safety for pregnant populations and novel antacid formulations.

• Safety of almagate for heartburn and reflux in pregnant women
• Evaluation of patient‑use robustness for inhaled tiotropium devices
• Impact of acid‑suppression therapy on maternal and fetal outcomes

Digestive studies prioritize maternal health and fetal safety.

Clinical work assesses treatments for hormonal disturbances, particularly vasomotor symptoms experienced during endocrine therapy for breast cancer.

• Fezolinetant efficacy on hot flash frequency and severity in women on adjuvant endocrine therapy
• Quality‑of‑life measurement in patients with moderate to severe vasomotor symptoms
• Comparative analysis of hormonal versus non‑hormonal management strategies

Results aim to expand therapeutic choices for hormone‑related conditions.

The department evaluates immune‑modulating therapies for conditions such as atopic dermatitis and allergic asthma, seeking to balance efficacy with safety.

• Upadacitinib combined with topical corticosteroids for moderate to severe atopic dermatitis
• Omalizumab dose reduction feasibility in allergic severe asthma
• Long‑term safety monitoring of biologic agents in immune‑mediated skin disease

Immune research integrates patient‑reported outcomes to gauge real‑world impact.

Oncology trials investigate novel agents and combination regimens in advanced solid tumors, aiming to improve anti‑tumor activity and patient survival.

• Anti‑tumor activity of RO7284755 alone or with atezolizumab
• Progression‑free survival assessment in experimental cancer therapies
• Safety profiling of emerging immuno‑oncology compounds

The cancer program emphasizes translational research to bridge laboratory findings with clinical benefit.

Research addresses symptomatic management, including pre‑operative anxiety and functional status, using both pharmacologic and non‑pharmacologic interventions.

• Comparison of music therapy versus midazolam for preoperative anxiolysis
• Evaluation of functional capacity in patients with chronic respiratory conditions
• Patient‑reported outcome measures for symptom burden across trials

Emphasis is placed on improving patient experience throughout the clinical journey.

A broad portfolio targets chronic lung disorders such as asthma, chronic obstructive pulmonary disease, bronchiectasis, and fibrotic interstitial lung disease, focusing on symptom control and disease progression.

• Inhaled antibiotic impact on colony‑forming units in bronchiectasis
• Oxygen therapy effects on physical activity in fibrotic ILD with exertional hypoxemia
• Dose optimization of omalizumab in allergic severe asthma

Respiratory studies incorporate functional testing and quality‑of‑life assessments.

Although fewer trials focus on oral and maxillofacial conditions, the site evaluates peri‑operative protocols for dental‑related surgeries and infection control.

• Assessment of postoperative infection rates after oral surgical procedures
• Evaluation of analgesic regimens for dental extractions
• Monitoring of antimicrobial stewardship in stomatognathic interventions

Ongoing work aims to integrate oral health considerations into broader clinical research.

Additional exploratory studies span pharmacokinetic modeling in healthy volunteers, anti‑doping substance exposure, and device performance assessments, reflecting the institution’s versatile research capacity.

• Pharmacokinetic profiling of oral and intranasal formulations in healthy subjects
• Detection of prohibited substances in anti‑doping investigations
• Robustness testing of tiotropium soft mist inhaler devices

These projects support methodological innovation and regulatory science.